We are live on ! Find out more
RGC icon

Regencell Bioscience
RGC

4 hedge funds and large institutions have $9.27K invested in Regencell Bioscience in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding

Funds holding: 2 → 4 (+2)

0.04% more ownership

Funds ownership: 0.16% → 0.19% (+0.04%)

21% less capital invested

Capital invested by funds: $11.7K → $9.27K (-$2.43K)

Holders
4
Holders Change
+2
Holders Change %
+100%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
+$1.34K
2
Morgan Stanley
Morgan Stanley
New York
+$395
3
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$206

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
1
Morgan Stanley
New York
$4.56K +$395 +950 +8%
BlackRock
2
BlackRock
New York
$3.33K – – –
TRCT
3
Tower Research Capital (TRC)
New York
$1.19K +$1.34K +3,230 New
Qube Research & Technologies (QRT)
4
Qube Research & Technologies (QRT)
United Kingdom
$185 +$206 +494 New

RGC Hedge Fund Activity: Q3 2023 in Review

4 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Regencell Bioscience (RGC) for Q3 2023, worth a combined $9.27K — down 21% from $11.7K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new RGC positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $1.34K.

  • 4 institutional investors held Regencell Bioscience (RGC) as of Q3 2023, up from 2 in Q2 2023.
  • Funds reported $9.27K of Regencell Bioscience stock for Q3 2023, down 21% quarter-over-quarter.
  • 2 funds opened new Regencell Bioscience positions in Q3 2023 and 0 closed out, a net change of +2 holders.
  • The largest Regencell Bioscience buyer in Q3 2023 was Tower Research Capital (TRC), an estimated $1.34K added.

Based on aggregated 13F filings for Q3 2023.